EGFR and non-small cell lung carcinoma: Although several routine biological parameters are related to outcomes after treatment with EGFR-TKIs for patients with advanced NSCLC harboring EGFR mutations [11,12], the prognostic value of bilirubin has not been comprehensively assessed.